EPS for Intra-Cellular Therapies (ITCI)

EPS in 2024 (TTM): -HK$6.79

According to Intra-Cellular Therapies's latest financial reports the company's current EPS (TTM) is -HK$6.83. In 2023 the company made an earnings per share (EPS) of -HK$11.45 an increase over its 2022 EPS that were of -HK$21.34.

EPS history for Intra-Cellular Therapies from 2014 to 2024

Annual EPS

Year	EPS	Change
2024 (TTM)	-HK$6.79	-40.74%
2023	-HK$11.45	-46.32%
2022	-HK$21.34	-22.29%
2021	-HK$27.46	8.02%
2020	-HK$25.42	20.9%
2019	-HK$21.02	-5.63%
2018	-HK$22.28	33.96%
2017	-HK$16.63	-21.19%
2016	-HK$21.10	-7.56%
2015	-HK$22.83	174.53%
2014	-HK$8.32

EPS for similar companies or competitors

Company	EPS	EPS differencediff.	Country
Xencor XNCR	-HK$17.02	149.43%	🇺🇸 USA
MediciNova MNOV	-HK$1.80	-73.56%	🇺🇸 USA
Curis CRIS	-HK$111.56	1,534.48%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions